Impact of a modified directly administered antiretroviral treatment intervention on virological outcome in HIV-infected patients treated in Burkina Faso and Mali

HIV Medicine

Volumn 10, Issue 3, 2009, Pages 152-156

  Pirkle, Catherine M ^a   Boileau, C ^b   Nguyen, V K ^c   Machouf, N ^d   Ag Aboubacrine, S ^e   Niamba, P A ^f   Drabo, J ^g   Koala, S ^h   Tremblay, C ^a   Rashed, S ^i,j  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Clinique l'Actuel   (Canada)

^e Hopital National du Point G   (Mali)

^f CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^g Centre Hospitalier National Yalgado Ouagadogou   (Burkina Faso)

^h Projet Fonds Mondial de Lutte contre le SIDA la Tuberculose et le Paludisme ^*  (Burkina Faso)

ⁱ MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^j SIDA 3 Project   (Mali)

more..

Author keywords

Adherence; Antiretroviral therapy; Drug resistance; HIV AIDS; Modified directly administered therapy; West Africa

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BURKINA FASO; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MALI; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; VIRUS LOAD; BLOOD; DRUG ADMINISTRATION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MEDICATION COMPLIANCE; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; BURKINA FASO; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MALI; MEDICATION ADHERENCE; PILOT PROJECTS; RNA, VIRAL; VIRAL LOAD;

EID: 61349088668     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00664.x     Document Type: Article

References (13)

1. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358: 410-414.
2. UNAIDS. Fact sheet: Sub-Saharan Africa. 2006. http://data.unaids.org/pub/ GlobalReport/2006/200605-FS_SubSaharanAfrica_en.pdf (accessed 30 March 2008).
3. Calmy A, Ford N, Hirschel B et al. HIV viral load monitoring in resource-limited regions: Optional or necessary? Clin Infect Dis 2007; 44: 128-134.
4. Koenig SP, Kuritzkes DR, Hirsch MS et al. Monitoring HIV treatment in developing countries. BMJ 2006; 332: 602-604.
5. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006; 367: 1870-1872.
6. Kagay CR, Porco TC, Liechty CA et al. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clin Infect Dis 2004; 38 (Suppl. 5): S414-S420.
7. Jaffar S, Govender T, Garrib A et al. Antiretroviral treatment in resource-poor settings: Public health research priorities. Trop Med Int Health 2005; 10: 295-299.
8. Aboubacrine SA, Niamba P, Boileau C et al. Inadequate adherence to antiretroviral treatment and prevention in hospital and community sites in Burkina Faso and Mali: A study by the ATARAO Group. Int J STD AIDS 2007; 18: 741-747.
9. Sylla M, Chamberland A, Boileau C et al. Characterization of drug resistance in a cohort of subjects on antiretroviral therapy infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. Antivir Ther; 13: 141-148.
10. Bates I, Maitland K. Are laboratory services coming of age in sub-Saharan Africa? Clin Infect Dis 2006; 42: 383-384.
11. Petti CA, Polage CR, Quinn TC et al. Laboratory medicine in Africa: A barrier to effective health care. Clin Infect Dis 2006; 42: 377-382.
12. Coutinho A, Mermin J, Ekwaru J et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. CROI 2008. Boston, USA; February 2008
13. Bangsberg DR, Charlebois ED, Grant RM et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17: 1925-1932.